Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'
Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'
复制标题
DOI：
10.1002/ehf2.12551
复制
发表时间：
2019-12-01
影响因子：
3.8
通讯作者：
Lyon, Alexander R.
中科院分区：
文献类型：
--
作者：
Anker, Markus S.;Hadzibegovic, Sara;Lyon, Alexander R.
虽然抗癌治疗，包括化疗，免疫治疗，放疗和靶向治疗，不断进步，心血管毒性已成为心脏病学家和肿瘤学家的主要挑战。这导致欧洲对心脏肿瘤科的需求不断增加，临床医生和研究人员的兴趣也越来越大。因此，在雅典举行的欧洲心脏病学会心力衰竭协会2019年会议制定了一项科学计划，其中包括关于该主题的四个专门会议沿着几个额外的讲座。在大会上讨论的要点包括心脏肿瘤学服务的实施和提供，心脏肿瘤学专家之间的合作，以及心脏毒性的风险分层，预防和早期识别。此外，会议还讨论了与心脏毒性作用相关的许多不同的抗癌疗法，并就如何在治疗前、治疗期间和治疗后治疗发生心血管疾病的癌症患者提供了指导。
While anti-cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly advancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing demand of cardio-oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meeting of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific programme that included four dedicated sessions on the topic along with several additional lectures. The major points that were discussed at the congress included the implementation and delivery of a cardio-oncology service, the collaboration among cardio-oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity. Furthermore, sessions addressed the numerous different anti-cancer therapies associated with cardiotoxic effects and provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment.